testosterone cypionate /ml
Phase 2Small molecule
testosterone cypionate /ml is one of 27 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
1
Indications
6
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Prednisone/prednisolone
RochePreclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Blood Pressure Monitoring1 trial
Prostate Cancer1 trial
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Completed·—·Phase 2·NCT03716739·136 enrolled
Testosterone1 trial
Transgender Men1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for testosterone cypionate /ml. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAzurity Pharmaceuticals